Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Bethanie Patton

Physician Assistant Abingdon, VA Physician Assistant

NPI 1992348254 CMS profile 11214248

24530 Falcon Place Blvd, Abingdon, VA 24211

Open in the dashboard

General payments

$5,737

271 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bethanie Patton of Abingdon, VA is reported in the CMS Open Payments database as having received $5,737 across 271 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,565 137
2024 General $1,867 88
2023 General $1,305 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bethanie Patton
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Bethanie Patton were reported at $2,565. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Bethanie Patton Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $1,305 $167 $52–$557 $160
2024 $1,867 $178 $55–$600 $164
2025 $2,565 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $1,875 82 payments
  2. GlaxoSmithKline, LLC. $745 47 payments
  3. Genzyme Corporation $552 31 payments
  4. Regeneron Healthcare Solutions, Inc. $460 27 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $362 12 payments
  6. Mylan Specialty L.P. $357 12 payments
  7. Insmed, Inc. $249 16 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $244 12 payments
  9. Sanofi-Aventis U.S. LLC $174 2 payments
  10. Baxter Healthcare $158 8 payments
  11. Other $560 22 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $5,429 266 payments
  2. Education $309 5 payments
Products named General payments · program years 2023–2025
  1. DUPIXENT Immunology $726 33 payments
  2. FASENRA $601 24 payments
  3. TEZSPIRE $588 20 payments
  4. TRELEGY ELLIPTA $488 28 payments
  5. AIRSUPRA $481 20 payments
  6. BREZTRI $399 19 payments
  7. YUPELRI $396 14 payments
  8. NUCALA $257 19 payments
  9. DUPIXENT Inflammation And Immunology $253 12 payments
  10. Arikayce $215 14 payments
  11. Other $2,105 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

2,142

Median for Physician Assistant: 241

Drug cost

$729,055

Median for Physician Assistant: $4,110

Branded share of claims

86.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 299 $209,901
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 258 $135,110
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 162 $121,924
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 120 $56,266
Symbicort Budesonide/Formoterol Fumarate Brand 181 $51,111
Spiriva Respimat Tiotropium Bromide Brand 60 $36,784
Bevespi Aerosphere Glycopyrrolate/Formoterol Fum Brand 46 $22,641
Advair Hfa Fluticasone Propion/Salmeterol Brand 34 $19,184
Breo Ellipta Fluticasone/Vilanterol Brand 35 $14,724
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 92 $13,260

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$39,044

Medicare's payments for the services billed

Medicare patients

186

Average age 73

Services billed

553

108 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 73%
Ischemic heart disease 39%
Arthritis 35%
Diabetes 34%
Chronic kidney disease 32%
Heart failure 28%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $253
  • GENZYME CORPORATION $96
  • SANOFI-AVENTIS U.S. LLC $95
$444 — —
YUPELRI
  • Mylan Specialty L.P. $240
$240 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $239
$239 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $168
$168 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $141
$141 299 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

271 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record